| 2026-08-11 | Press release | Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-07 | 8-K | Form 8-K/A, Item 5.02 |
| 2026-08-06 | Press release | Tango Therapeutics Announces Executive Chair Transition |
| 2026-08-06 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-23 | Deck | Tango Therapeutics Corporate Presentation |
| 2026-06-23 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-22 | Press release | Tango Therapeutics Appoints Robert Azelby to Board of Directors |
| Transcript | Earnings call transcript |
| 2026-06-10 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-09 | Press release | Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering |
| 2026-06-08 | Deck | Investor presentation · Jun 2026 |
| 2026-06-08 | Press release | Tango Therapeutics Announces Proposed $500 Million Public Offering |
| 2026-06-08 | Press release | Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pa |
| 2026-06-08 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-05 | Press release | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-13 | Press release | Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights |
| 2026-05-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-13 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-08 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-04 | Press release | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-17 | Proxy | Definitive proxy statement |
| 2026-04-15 | Press release | Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat |
| 2026-04-15 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-06 | Press release | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-05 | Press release | Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights |
| 2026-03-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-03 | Press release | Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 2026-01-08 | Press release | Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor |
| 2026-01-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-05 | Press release | Tango Therapeutics Appoints Sung Lee to Board of Directors |
| 2026-01-05 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-21 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-24 | 8-K | Form 8-K, Item 1.01 |